GlassScriptPhysician profile
Audra Deardorf
NPI 1467946111
$2,101.00
in general payments reported to CMS, 2019-2025
19 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $41.82 · 2022: $11.71 · 2023: $79.04 · 2024: $404 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,047.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $389.75 | 2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $293.04 | 2025 | |
| Lilly USA, LLC | $227.66 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Phathom Pharmaceuticals, INC. | $162.62 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $153.39 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $142.13 | 2025 | Caplyta |
| Novo Nordisk INC | $136.42 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Exact Sciences Corporation | $117.62 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $90.38 | 2023-2025 | Otezla, Repatha, Otezla |
| Pfizer INC. | $89.62 | 2023-2025 | |
| Axsome Therapeutics, INC. | $85.84 | 2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.39 | 2025 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $39.37 | 2025 | Trintellix |
| Abbott Laboratories | $36.24 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $29.27 | 2025 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.13 | 2025 | Xifaxan |
| Dexcom, INC. | $18.49 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $16.79 | 2025 | Gemtesa |
| Corium, LLC | $8.85 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audra Deardorf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.